The CSL Ltd (ASX: CSL) share price has suffered heavily within the last two years. As the below chart shows, the ASX biotech share giant has now dropped by around two-thirds since August 2024.
It has been the worst-performing ASX blue-chip by far in that period and it just keeps falling.
The business may become oversold if it keeps declining, creating a rebound opportunity for contrarian investors.
Have we already reached that oversold level? I don’t have a crystal ball to refer to, but we can look at what analysts think of the CSL share price and whether it’s undervalued.
Image source: Getty Images
CSL share price target
A price target tells investors where an analyst thinks the share price will be in 12…
